Impact of a a pharmaceutical consultation service on palliative care pharmacotherapy
Not Applicable
- Conditions
- Palliative care patients (no specific underlying disease)
- Registration Number
- DRKS00007696
- Lead Sponsor
- Klinikum der Universität MünchenKlinik und Poliklinik für Palliativmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
• patients with life-limiting diseases (malignant and non-malignant)
• Age > 18 years
• admission to the palliative care unit at university hospital Munich or Cologne
• Interventiongroup: patients living in or around Munich
• patients able to communicate in German or English
• informed consent of the patient
• life expectancy of at least 4 weeks
Exclusion Criteria
patients unable to give consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method symptom burden of palliative care patients before and after discharge (measured with integrated Palliative Outcome Scale (IPOS) after admission, before discharge and weekly over 4 weeks after discharge)
- Secondary Outcome Measures
Name Time Method • Drug tolerability (trailmaking-test and anticholinergic load; within 48 h after admission)<br>• Drug-related problems (intervention group only; Pharmaceutical Care Network Europe Drug Related Problems, Priscus-List; during inpatient care)<br>• hospital admission after discharge (within 4 weeks after discharge)<br>• use of the drug information service (intervention group only; within 4 weeks after discharge)<br> • Support by doctor and pharmacist after discharge (within 4 weeks after discharge)<br>• changes to the drug regimen (within 4 weeks after discharge)<br>